Key facts
- This page summarizes Vifor (International) Ltd's Form 3 filing for Cara Therapeutics, Inc. (TVRD).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Oct 2021, 16:30.
Vifor (International) Ltd - 20 Oct 2021 Form 3 Insider Report for Cara Therapeutics, Inc. (TVRD)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TVRD
- Reported as of
- 20 Oct 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 21 Oct 2021, 16:30:22 UTC
- Prior SEC filing
- 13 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- VIFOR (INTERNATIONAL) LTD., By: /s/ Georg Frey, Title: Head Legal Corporate, By: /s/ Markus Frenzen, Title: Group Treasurer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vifor (International) Ltd filed Form 3 for Cara Therapeutics, Inc. (TVRD) on 21 Oct 2021.
Change
- Previous filing in this sequence was filed on 13 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARA
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,396,770
- Date
- 20 Oct 2021
- Ownership
- See Notes
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor (International)"), this Form 3 is being filed by Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), and Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 3 (the "Subject Securities").
Footnote F2
VFMCRP's beneficial ownership of the common stock referred to herein is being reported solely because VFMCRP may be deemed to beneficially own 6,221,943 shares of Common Stock of Cara Therapeutics, Inc. as a result of its right to acquire such shares upon exercise of an option granted to it by Vifor (International). Vifor Pharma's beneficial ownership of the common stock referred to herein is being reported solely because Vifor Pharma may be deemed to beneficially own 7,396,770 shares of Common Stock of Cara Therapeutics, Inc. as a result of its indirect ownership of 100% of the equity interests of Vifor (International) and 55% of the equity interests of VFMCRP.
Footnote F3
Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.